Compare Kinross Gold Corporation (KGC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs GeneDx Holdings Corp — how do they compare? Kinross Gold Corporation trades at $23.7 (market cap $27.62B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Kinross Gold Corporation is far larger — about 13.7× GeneDx Holdings Corp's market cap, and Kinross Gold Corporation pays a 0.69% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and GeneDx Holdings Corp for 19 Days on average.
| KGC | WGS | |
|---|---|---|
Market Cap | $27.62B | $2.02B |
Volume | 6,347,266 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $167.51 |
52-Week Low | $22.47 | $34.51 |
Typical Hold Time | 53 Days | 19 Days |
Enterprise Value | $25.70B | $2.05B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
